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Summary. This study aims to investigate whether the 
immunohistochemical expression of galectin-8 could be 
used as a diagnostic marker in tumor tissues of various 
histogenetic origins including specimens from epithelial 
(n=145), mesenchymatous (n=16), adipous (n=10) and 
central and peripheral nervous system (n=25) tissue, and 
4 mesotheliomas. Immunohistochemical reactions were 
carried out with a polyclonal anti-galectin-8 antibody 
and histological slides from tissues derived from the files 
of the Laboratory of Anatomopathology of University 
Erasmus Hospital, Brussels. Formalin-fixed paraffin- 
embedded tissues of 45 normal cases as well as 41 
benign and 114 malignant tumors were studied. Marked 
decreases in immunohistochemical galectin-8 expression 
were obsewed in colon (p=0.001), pancreas (p=0.007), 
liver (p=0.0008), skin (p=0.002) and larynx (p=0.02) 
tissue when comparing malignant tissue to normal tissue 
andlor benign tumors. The reverse relationship was 
observed for breast tissue (p=0.007). No statistically 
significant differences (p>0.05) were detected when 
comparing normal tissue andlor benign to malignant 
tumors in lung, bladder, kidney, prostate and stomach 
tissue. Significant galectin-8 expression was also 
measured in non-epithelial tissue including tumors of the 
central and peripheral nervous system as well as in 
skeletal muscle and mesotheliomas. Immunohisto- 
chemical monitoring of galectin-8 thus reveals an organ- 
type-dependent regulation of expression upon malignant 
transformation of various tissue types of epithelial 
origin. This observation will prompt further studies to 
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delineate any relationship with prognosis 
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lntroduction 
A growing number of adhesion molecules which 
play a notable role in tumor cell migration and invasion 
(Thiery et al., 1988; Streit et al., 1996; Kaltner and 
Stierstofer, 1998) are referred to as lectins. Currently, 
these sugar receptors are divided into five families 
according to their carbohydrate specificities and the 
structural motif of their carbohydrate recognition 
domains (CRD) (Gabius, 1997). Of these five groups of 
lectins, the galectins share a cation-independent binding 
to galactosides and a jelly-rol1 motif with a series of 
invariant amino acids in the binding pocket (Harrison, 
1991; Drickamer and Taylor, 1993; Barondes et al., 
1994; Kasai and Hirabayashi, 1996; Gabius, 1997, 2000; 
Hirabayashi, 1997), and display various common 
features such as  a lack of disulfide bridges, 
glycosylation, and signal sequence and, in most cases, 
their N-terminal amino acids are acetylated (Kasai and 
Hirabayashi, 1996; Gabius, 1997; Hirabayashi, 1997). 
When secreted from cells galectins can interact with a 
set of extracellular proteins including, for example, 
laminins, fibronectin and a7/a1B1 integrins (Harrison, 
1991; Drickamer and Taylor, 1993; Barondes et al., 
1994; Kasai and Hirabayashi, 1996; Gabius, 1997; 
Hirabayashi, 1997). Based on the spatial arrangement of 
the CRD(s), the members of this lectin family are 
classified into proto-, chimera-, and tandem-repeat types 
Galectin-8 expression in normal and tumor tissue 
(Gabius, 1997; Hirabayashi, 1997). In 1994 it was 
proposed that mammalian galectins be numbered 
according to the chronology of discovery (registration to 
GenBank), and on the basis of this system, 11 
mammalian galectins have been registered to date 
(Gabius, 1997; Hirabayashi, 1997; Dunphy et al., 2000). 
Galectin-1, -2, -5, -7, -10 and -11 belong to the proto- 
type subgroup of galectins; galectin-3 is so far the 
unique representative of the chimera-type subgroup; and 
galectins-4, -6, -8 and -9 belong to the tandem-repeat 
subgroup (Gabius, 1997; Hirabayashi, 1997). Due to the 
potential of galectins to participate in cell-celllmatrix 
adhesion, growth regulation and interna1 processes such 
as pre-mRNA splicing (Gabius, 1997; Hirabayashi, 
1997), it is reasonable to propose an involvement of 
these proteins in tumor development. Moreover, their 
interaction with glycans can provide clues on the 
significance of glycosylation aberrations in malignant 
transformation, which are currently primarily catalogued 
but not functionally understood. 
To date, only very few data have been published on 
galectin-8 (Hadari et al., 1995, 1997; Su et al., 1996), 
prompting to initiate investigation of expression of this 
endogenous lectin, the first tandem-repeat-type galectin, 
in tumor histology. cDNA for galectin-8 was cloned by 
Hadari et al. (1995) from a rat liver cDNA library, and a 
cDNA encoding human galectin-8 was then isolated 
from a human brain hippocampus library by means of 
the full-length rat cDNA used as a probe (Hadari et al., 
1997). The product of this clone is a 35-kDa protein 
consisting of two domains of about 140 amino acids, 
each of these domains containing a single CRD. These 
two domains are joined by a 32 amino acid residue-long 
link peptide (Hadari et al., 1995, 1997), and no 
homology with any known protein is found in this region 
(Hadari et al., 1997). Galectin-8 resembles galectin-4 
(Oda et al., 1993), galectin-6 (Gitt et al., 1998) and also 
galectin-9 (Türeci et al., 1997; Wada and Kanwar, 1997) 
as well as a galectin homologue from Caenorhabditis 
elegans (Hirabayashi et al., 1996), in its typical 
arrangement of two CRDs covalently linked by a 
connecting peptide stretch. At nucleic acid level 
galectin-8 is 50% and 45% homologous with galectin-4 
and the nematode galectin, respectively, while at amino 
acid level galectin-8 shares a 34% and 31% identity 
(Hadari et al., 1997). Since the two carbohydrate 
recognition domains of galectin-8 are related but 
distinct, these two domains are expected firstly to be 
structurally different and secondly to interact with 
different sets of carbohydrate ligand, thereby serving as 
a crosslinking molecule (Hadari et al., 1995; Gabius, 
1997). 
The aim of the present work is to investigate 
whether the level of expression of galectin-8 differs 
significantly between normal, benign and malignant 
tumors arising from tissues of different embryological 
origins. For this purpose, we characterized the levels and 
patterns of immunohistochemical expression of galectin- 
8 in 200 specimens including 45 normal cases as well as 
41 benign and 114 malignant tumors. 
Materials and methods 
Specimens 
A series of 200 retrospective formalin-fixed 
paraffin-embedded cases were analyzed in order to 
determine whether they exhibited positivity in 
immunohistochemical processing aimed at galectin-8 
detection. These 200 cases included 45 normal cases as 
well as 41 benign and 114 malignant tumors. The 
histological origin of each of the 200 tissues is detailed 
in the Results. On the one hand, benign, normal or 
reactively altered tissues, and, on the other, malignant 
tumors (at least grade 11 according to the World Health 
Organization) were studied. 
lmmunohistochemical staining 
Two sections of 5-pm each were taken from each 
specimen and subjected to processing with the anti- 
galectin-8 antibody (raised in rabbits against the 
recombinant protein) and kit reagents. The antibody 
specificity was ascertained by Western blotting analysis 
using recombinant galectins-1, -3, -4 and -7 as controls, 
referring staining with the polyclonal antibody to 
galectin-8 and its variants with peptide linker extensions. 
This staining procedure was previously described for the 
immunohistochemical characterization of various types 
of galectin-1 and -3 and galectin-binding sites in renal 
(Franpis et al., 1999), head and neck (Choufani et al., 
1999) and smooth muscle (Schwarz et al., 1999) tumors. 
Briefly, incubation with the anti-galectin-8 antibody was 
carried out at 2521 "C for 60 minutes. The dilution used 
for the anti-galectin-8 antibody was 1:500. 
Immunoreaction was developed through the application 
of avidin-biotin-peroxidase complex (ABC) kit reagents 
(Vector Labs, Burlingame, CA), with diamino- 
benzidine/H202 as chromogenic substrates (Choufani et 
al., 1999; Francois et al., 1999; Schwarz et al., 1999). 
The control tissues were incubated with the 
corresponding pre-immune sera, with the second 
antibody only, or with the polyclonal anti-galectin-8 
antibody preabsorbed with recombinant galectin-8. 
Omission of the incubation step with the labeled marker 
served to exclude staining by any of the binding kit 
reagents, such as the mannose-rich glycoprotein, 
horseradish peroxidase acid avidin. Counterstaining was 
carried out with hematoxylin. 
Some immunohistochemical patterns of staining 
(obtained with the anti-galectin-8 antibody in various 
types of normal tissue, and also in benign and malignant 
tumors) are illustrated in the Results. 
Evaluation of immunohistochemical staining 
The staining of the tissue specimens was scored 
using a semi-quantitative scoring system described by 
Galectin-8 expression in normal a n d  tumor tissue 
Bresalier et al. (1997), who characterized the level of the 
immunohistochemical expression of galectin-3 in human 
brain tumors. For each specimen analyzed the system 
proposed by Bresalier and colleagues yields an average 
staining intensity score that takes into account tumor 
heterogeneity. Al1 the fields of each single tissue were 
examined, and the staining intensity and distribution 
were assessed in each field by means of a x10 objective. 
The staining intensity was scored as absent (O), weak 
(1), moderate (2) or strong (3), and the percentage of 
tumor cells stained was determined. A staining score for 
each specimen was calculated as "intensity x percentage 
of positive tumor cells / 100" (Bresalier et al., 1997). 
Statistical analyses 
The Mann-Whitney rank test (for comparing 2 
groups) was used to compare the irnmunohistochemical 
galectin-8 expression in normal tissue andlor benign 
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Fig. 1. Characterization of the level of immunohistochemical expression 
of galectin-8 in 76 specimens including normal or benign (the open 
symbols in the BEN groups) and malignant tumors (the black symbols in 
the MAL groups) in epithelial tissue from breast (n=17). colon (n=18), 
pancreas (n=13), stomach (n=8) and liver ( ~ 2 0 ) .  lmmunohistochemical 
galectin-8 expression was semi-quantitatively determined using a 
staining score which corresponds to staining intensity multiplied by the 
% of positive tumor cells 1 100. lntensity of staining was scored as 
absent (O), weak ( l ) ,  moderate (2) or strong (3). The 17 breast 
specimens included 4 cases of fibrocystic dysplasia (open dots), 4 
tubular adenomas (open triangles), 4 invasive ductal carcinomas NOS 
(black dots) and 5 lobular carcinomas (black triangles). The 18 colon 
tissues included 7 cases of normal mucosa (open dots), 5 low to 
moderate dysplasias (open triangles) and 6 adenocarcinomas (black 
dots). The 13 specimens referred to as "pancreas" cases included in 
fact both pancreas and gallbladder cases, e.g. 6 normal (open dots = 
normal pancreas and open triangles = normal gallbladders) and 7 
malignant (black dots = pancreatic adenocarcinomas and black triangles 
= cholangiocarcinomas) cases. The 8 stomach cases included 4 
specimens of normal mucosa (open triangles) and 4 adenocarcinomas 
(black triangles). The 20 liver cases included 5 normal cases (open 
dots), 5 cirrhotic livers (open squares), 5 hepatoblastomas (black 
squares) and 5 hepatocarcinomas (black dots). The statistical intra- 
group comparisons are listed in the upper part of the figure (n.s.: not 
significant). 
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lesions in relation to their malignant counterparts. Al1 
the statistical analyses were carried out using Statistica 
(Statsoft, Tulsa, OK, USA). 
Results 
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Characterization of immunohistochemical galectin-8 
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Figs, 1, 2 detail the staining score values obtained 
with the anti-galectin-8 antibody in 11 distinct groups of 
epithelial tissues. The data from these figures clearly 
indicate that no global conclusion can be drawn with 
respect to the positivity in these various epithelial 
tissues. In detail, no statistically significant differences 
in this parameter were observed between the benign 
cases (including the normal cases or the benign tumors, 
or both) and the malignant tumors in the five epithelial 
tissue groups covering the stomach (Fig. l) ,  the lung 
(Fig. 2), the bladder (Fig. 2), the kidney (Fig. 2) and the 
prostate (Fig. 2). 
Breast cancer cases constituted the only group of 
tissue to exhibit a higher immunohistochemical galectin- 
8 expression in the malignant as opposed to the benign 
cases (Fig. 1). This feature is clearly evident in Figs. 3A 
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Flg. 2. The legend to Fig. 2 is identical to that for Fig. 1 (except for the 
origin of the analyzed tumors). Sixty-nine epithelial tissues were 
analyzed and included skin (n = 20), head and neck (n=8), lung (n=14), 
bladder (n=9), kidney (n=8) and prostate (n=10) cases. The BEN groups 
included normal specimens or benign tumors while the MAL groups 
included malignant tumors. The 20 skin cases included 5 normal 
specimens (open triangles), 5 molluscum pendulum (open dots), 5 
spinocellular carcinomas (black triangles) and 5 basal cell carcinomas 
(black dots). The 8 head and neck cases included 4 normal cases (open 
triangles) and 4 squamous cell carcinomas (black triangles) of the 
larynx. The 14 lung specimens included 4 normal cases (open dots), 5 
squamous carcinomas (black triangles) and 5 adenocarcinomas (black 
squares). The bladder group included 4 normal cases (open dots) and 5 
transitional carcinomas (black dots). The 8 kidney cases included 4 
normal specimens (open dots) and 4 renal carcinomas (black dots). The 
10 prostate specimens included 5 benign hyperplasias (open dots) and 
5 adenocarcinomas (black dots). 
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Galectin-8 expression in normal and tumor tissue 
and 3B at morphological level. Higher expression of immunoreactivity was observed in the remaining 5 
galectin-8 in the malignant as opposed to the benign groups of epithelial tissues under study when comparing 
breast tissue specimens were mainly detected in lobular the malignant to the benign tissue. This feature concerns 
carcinomas, one particular subgroup of malignant breast tissue from colon (Fig. 1, 3C,D), pancreas (in fact both 
cancers, and not in any type of breast cancer (Fig. 1). pancreas and gallbladder; Fig. l),  liver (Figs. 1, 3E,F), 
A statistically very significant decrease in skinandlarynx(Fig.2).Inthesecases,thisdecreasewas 
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Fig. 3. Morphological illustrations of immunohistochemical galectin-8 expression in sections of a breast tubular adenoma (a, x 400), a breast lobular 
carcinoma (b, x 400) normal colonic glands (c, x 400), a colon adenocarcinoma (d, x 400) a normal l ie r  (e, x 400) and a hepatocarcinoma (1, x 400). 
While expression markedly increased from the benign to the malignant breast tissue, it decreased from the benign to the malignant colon and l ie r  
tissue. 
Galectin-8 expression in normal and  tumor tissue 
generally accompanied by a modification in the 
subcellular location of galectin-8. For example, many 
nuclei exhibited marked staining in the normal 
specimens and benign tumors of the colon, while the 
nuclear location of galectin-8 disappeared in malignant 
colon. 
In order to give some information regarding the 
distinction between a low percentage of positive cells 
displaying strong staining intensities and a higher 
percentage of cells with weak intensities, we detailed (as 
an example) such data on liver tissues in Fig. 4. In 
normal and cirrhotic livers (BEN group), the staining 
intensities of positive cells appeared to be moderate to 
strong, and the percentage of positive cells per 
specimens varied between 80 and 100%. In the MAL 
group (hepatoblastomas and hepatocarcinomas) the 
percentage of positive cells per specimens varied 
between 40 and 100%, and the staining intensity of 
positive cells between weak to moderate. 
Characterization of immunopositivity in benign and 
malignant non-epithelial tissues 
Fig. 5 shows that no striking differences were 
obsewed between the various groups of tissue of non- 
epithelial origin with respect to immunohistochemical 
galectin-8 expression. Indeed, while both the benign and 
the malignant smooth muscle tumors exhibited low 
levels of galectin-8, the skeletal tissues, whether normal 
or malignant, exhibited high amounts. Variable extents 
of immunopositivity were obsewed in various groups of 
tumors of the central and peripheral nervous system 
(Fig. 5), and also in mesotheliomas (Fig. 5). 
We herein initiate work on the expression of 
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Fig. 4. Expression of galectin-8 in liver tissues based on staining 
intensity (Y axis) and percentage of tissue stained (X axis). Solid 
symbols represent individual specimens as follows: normal cases as 
open dots (A), cirrhotic as open squares (B), hepatoblastomas as black 
dots (C) and hepatocarcinomas as black squares (D). 
galectin-8 in various normal or altered tissues and 
neoplastic lesions. The study involves a large number of 
tissues with sometimes a low number of specimens in 
each group. We are aware of this weakness but let us 
remember that our main goal is to localize tandem- 
repeat-type galectin in normal specimens, benign and 
malignant lesions in tissues with different embryological 
origins. Using Northern analysis Hadari et al. (1995) 
characterized the expression of galectin-8 in different rat 
tissues and reported that galectin-8 mRNA is highly 
expressed in lungs, and, to a lower extent, in liver, 
kidneys, spleen, hind-limb and cardiac muscles. These 
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Fig. 5. The legend to Fig. 5 is identical to that for Fig. 1 (except for the 
origin of the analyzed tumors). Fifty-five cases were analyzed and 
included 16 mesenchymatous and 10 adipous tissues, 4 
mesotheliomas, and 25 tumors of the central and peripheral nervous 
system. The tissues of mesenchymatous origin included 4 benign 
(uterine leiomyomas, open dots) and 4 malignant tumors (uterine 
leiomyosarcomas, black dots), 4 normal skeletal muscles (open dots) 
and 4 rhabdomyosarcomas (black dots). The adipous tissues included 5 
lipomas (open dots) and 5 liposarcomas (black dots). The tumors of the 
nervous system included 4 benign schwannomas (open dots) and 4 
malignant neme sheath tumors (MNSTs, black dots), 4 primitive 
neuroectodermal tumors (the PNET group), 5 medulloblastomas (the 
MEDUL. Group) and 8 astrocytic tumors (3 WHO grade II  
(astrocytomas, open dots), 2 WHO grade III (anaplastic astrocytomas, 
black dots) and 3 WHO grade IV (glioblastomas, black squares) cases. 
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Galectin-8 expression in normal and tumor tissue 
biochemical data on rodent tissues are partly 
corroborated by our immunohistochemical data on 
human specimens. Indeed, we also observed significant 
amounts of galectin-8 in normal lung tissue, but we 
observed increased levels in normal liver, colon and skin 
tissue. Hadari et al. (1997) also report that they have 
been able to demonstrate high levels of galectin-8 
expression in 129 human lung carcinoma cells, and 
argue that like galectin-3, whose expression is also up- 
regulated in certain cancer types like those of the colon, 
galectin-8 could represent a promising marker of 
malignant transformation. However, our data reveal that 
a high level of galectin-8 is not a general feature of lung 
cancer. Indeed, we obtained no statistically significant 
differences for immunopositivity between normal and 
malignant epithelial lung tissue. In addition, we 
observed very significant decreases in galectin-8 
expression in maiignant colon, skin, liver and pancreas 
tissue, for example, when compared to their normal or 
benign counterparts. 
Following the initial cloning of rat galectin-8 cDNA, 
surface-epitope masking and expression cloning were 
instrumental to identify a tumor antigen as a human 
homologue of galectin-8 (Su et al., 1996). At the protein 
level, it shares 81% homology with the rat protein. 
Based on immunological screening it is referred to as 
human prostate carcinoma tumor antigen (PCTA-l), 
which is selectively expressed in prostate carcinoma 
cells but not in normal prostate or benign prostatic 
hyperplasias (Su et al., 1996). As reported by Hadari et 
al. (1997), PCTA-1 differs in eight amino acids (at 
positions from No 56-205) from galectin-8 expressed in 
human brain, but the reason and consequences for this 
variability are presently unknown. It is possible that such 
variability could represent a polymorphism of human 
galectin-8, for example, or the expression of a mutant 
form of galectin-8 in prostate carcinoma cells (Hadari et 
al., 1997). Concerning immunohistochemistry on 
prostate samples, the RT-PCR data on four cell lines and 
15 tissue samples and the immunohistochemical data on 
frozen sections reported by Su et al. (1996) are not in 
line with our data on fixed sections. Our data indicate 
that the cross-reactive protein is expressed at very low 
levels in normal prostatic tissues as well as in benign 
hyperplasias or prostatic adenocarcinomas. Still, 
preliminary results revealed that the level of expression 
of galectin-8, determined by means of Western blotting, 
is significantly higher in prostatic adenocarcinomas, 
compared to normal prostatic tissue, again emphasizing 
the fact that differences in tissue handling, and the 
methodologies used for detection, might affect the 
results. 
Conflicting data sets on the levels of expression of 
galectins-1 and -3 in various organ types were also 
reported, pointing to the assessment technique, 
processing, tumor area sampling and selection as non- 
negligible parameters (Irimura et al., 1991; Lotan et al., 
1991; Castronovo et al., 1992; Lotz et al., 1993; 
Schoeppner et al., 1995). These studies with differences 
in design and samples intimate that it is essential to be 
cautious with generalizations. In this respect, it is 
noteworthy that among breast cancer types 
immunopositivity was high in the examined lobular 
carcinomas of the breast, but not in the invasive ductal 
adenocarcinomas NOS (see Fig. 1). 
Concerning potential functional implications, a 
typical feature of galectins warrants a comment. 
Galectin-8 lacks the classical signal sequence of a 
transmembrane region, and despite lacking this 
sequence, like other galectins (Cooper and Barondes, 
1990; Lindstedt et al., 1993; Sato and Hughes, 1994), 
galectin-8 is externalized by an atypical secretory 
mechanism. Hence galectin-8, like other galectins, is 
expected to function, at least in part, extracellularly 
(Hadari et al., 1997). Atypical secretion is not a unique 
property of galectins, since other cytoplasmic proteins 
like thioredoxin (Rubartelli et al., 1992), interleukin-lB 
(Siders et al., 1993), basic fibroblast growth factor 
(Mignatti et al., 1992) and certain S100 proteins (Schafer 
and Heizmann, 1996) lack signal sequences, yet are 
externalized and function extracellularly. The 
extracellular function of galectin-8 is still unknown but it 
is intriguing that a PCTA-1-specific monoclonal 
antibody (11 injections of 200 mg each) reduced the size 
of DU-145 tumors in seven of nine athymic nude mice 
(Su et al., 1996). It may well act at several biological 
levels including cell adhesion, cell proliferation, 
apoptosis and cell migration, as already evidenced for 
other galectins (see Gabius, 1997; Kaltner and 
Stierstorfer, 1998; Perillo et al., 1998; André et al., 1999 
for review, and Kopitz et al., 1998 for an example on 
neuroblastoma cells). 
In conclusion, the present data show that 
immunoreactivity with a galectin-8-specific polyclonal 
antibody in fixed tissue sections markedly decreases in 
malignant tissues of the colon, the pancreas, the iiver, 
the larynx and the skin, as compared to their normal or 
benign tumor counterparts. The reverse relationship was 
observed for mammary tissue, but a clear explanation 
cannot be offered presently. These data warrant further 
investigation that must be carried out on significantly 
larger series of cases in consideration of inter- and 
intratumoral heterogeneity to determine whether such 
decreases in galectin-8 expression are associated with 
prognosis in these tissues. 
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